Company profile for Dispatch Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Dispatch Bio, founded in 2022, is driven by a bold mission: create a world where all solid tumor cancer patients can be cured. Using our first‑in‑class Flare platform, we combine a tumor-specific viral vector with immunotherapy to tag and eliminate cancer cells precisely and powerfully. Based in Philadelphia and San Francisco, we collaborate with world‑class researchers and operate at the convergence of cutting‑edge sc...
Dispatch Bio, founded in 2022, is driven by a bold mission: create a world where all solid tumor cancer patients can be cured. Using our first‑in‑class Flare platform, we combine a tumor-specific viral vector with immunotherapy to tag and eliminate cancer cells precisely and powerfully. Based in Philadelphia and San Francisco, we collaborate with world‑class researchers and operate at the convergence of cutting‑edge science and translational impact.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
25 N. 38th St. Suite 600 Philadelphia, PA 19104
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/carsgen-and-dispatch-bio-announce-clinical-collaboration-to-evaluate-flare-platform-and-zevor-cel-in-solid-tumors-302658143.html

PR NEWSWIRE
12 Jan 2026

https://www.businesswire.com/news/home/20260111212910/en/Dispatch-Bio-Announces-FDA-Clearance-of-IND-Application-for-DISP-10-a-First-in-Class-Immunotherapy-Treatment-in-Solid-Tumors

BUSINESSWIRE
12 Jan 2026

https://www.businesswire.com/news/home/20251103154690/en/Dispatch-Bio-Announces-Clinical-Supply-and-Collaboration-Agreement-with-Bristol-Myers-Squibb-in-Solid-Tumors

BUSINESSWIRE
04 Nov 2025

https://www.businesswire.com/news/home/20251103493641/en/Dispatch-Bio-Unveils-First-Clinical-Program-and-Presents-Data-Supporting-Flare-Platform-at-Society-for-Immunotherapy-of-Cancer-SITC-2025-Annual-Meeting

BUSINESSWIRE
04 Nov 2025

https://www.businesswire.com/news/home/20250929659486/en/Dispatch-Bio-Appoints-Mauro-Avanzi-M.D.-Ph.D.-as-Chief-Medical-Officer

BUSINESSWIRE
30 Sep 2025

https://www.businesswire.com/news/home/20250722291236/en/Dispatch-Bio-Launches-to-Deliver-Universal-Treatment-Across-Solid-Tumors-with-Novel-Immunotherapy-Approach

BUSINESSWIRE
23 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty